Abstract:Abstract Introduction Prader-Willi syndrome (PWS) is a genetic, neurodevelopmental disorder characterized by global hypothalamic dysfunction that results in a variety of symptoms including behavioral disturbance, hyperphagia, and excessive daytime sleepiness (EDS). Pitolisant is approved for the treatment of EDS or cataplexy in adults with narcolepsy. In a phase 2, proof-of-concept study, pitolisant showed trends of reduction in EDS relative to placebo in patients with PWS. Methods This multicenter, randomized, double-blind, placebo-controlled, phase 3 study will evaluate the efficacy and safety of pitolisant in patients with PWS. The study will enroll patients ≥6 years of age with a genetically confirmed diagnosis of PWS, and have EDS as confirmed by the investigator. Selected exclusion criteria include patients with symptoms or diagnosis of psychosis or schizophrenia, inadequately treated sleep disordered breathing, and moderate or severe hepatic or renal impairment. Eligible patients will be randomly assigned (1:1) to receive pitolisant (weight-based dosing: 8.9-44.5 mg/d) or matching placebo tablets. The 11-week double-blind period will be followed by an optional 52-week open-label extension. Results Up to 100 patients per group will be enrolled. The primary endpoint will be change from baseline at Week 11 in EDS as measured by the PROMIS-SRI (Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment [Parent Proxy]). The secondary endpoints will include behavioral disturbance as measured by the Aberrant Behavior Checklist-Community domains (irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech), Caregiver Impression of Severity for EDS, Clinician Global Impression of Severity for EDS, Epworth Sleepiness Scale for Children and Adolescents, and the Hyperphagia Questionnaire for Clinical Trials in conjunction with the Food Safe Zone Questionnaire. Safety assessments will include incidence and severity of adverse events, clinical laboratory tests, vital signs, and 12-lead ECG. The study is expected to start enrolling patients in 2024. Conclusion This study is designed to determine whether pitolisant is efficacious in the treatment of EDS in patients with Prader-Willi syndrome and to further characterize its safety profile in this patient population. Support (if any) Harmony Biosciences, LLC

0648 Phase 3 Randomized Placebo-Controlled Trial of Pitolisant for Excessive Daytime Sleepiness in Prader-Willi Syndrome

0631 Phase 2, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome: Primary and Secondary Efficacy Analyses

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study

A randomized double-blind placebo-controlled clinical trial of Guanfacine Extended Release for aggression and self-injurious behavior associated with Prader-Willi Syndrome

Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study

Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study

0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Blind, Randomized Trial in Patients with Idiopathic Hypersomnia

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety

Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD

The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome

Excessive daytime sleepiness in obstructive sleep apnea: Indirect treatment comparison of wake-promoting agents in patients adherent/nonadherent to primary OSA therapy

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis

Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome

0651 Pharmacokinetics of Morning and Nighttime Doses of KP1077, an Investigational Treatment for Idiopathic Hypersomnia

1215 Adjunctive Use of Solriamfetol in Pediatric Excessive Daytime Sleepiness: A Single Center Experience

Clinical and Molecular Characterization of Prader-Willi Syndrome

Preserved Sleep for the Same Level of Respiratory Disturbance in Children with Prader-Willi Syndrome

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial

Pramipexole in Peritoneal Dialysis Patients with Restless Legs Syndrome (RLS): a Protocol for a Multicentre Double-Blind Randomised Controlled Trial

A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings

0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study